

Company registration number: 208815.

**MAHONYS (PHARMACY) LTD.
Trading as Mahonys**

**Unaudited abridged financial statements
for the financial year ended 31 August 2025**

MAHONYS (PHARMACY) LTD.

Contents

	Page
Directors and other information	1
Balance sheet	2
Notes to the financial statements	3 - 5

MAHONYS (PHARMACY) LTD.

Directors and other information

Directors	Mr. Michael Mahony Ms. Sinead Mahony
Secretary	Mr. Michael Mahony
Company number	208815.
Registered office	22/23 High Street, Kilkenny.
Business address	22/23 High Street, Kilkenny.
Accountants	Patrick J. Kennedy & Co., Chartered Accountant, 6 William Street, Kilkenny.
Bankers	AIB plc PermanentTSB
Solicitors	M/S Lanigan & Nolan, Kilkenny.

MAHONYS (PHARMACY) LTD.

**Balance sheet
As at 31 August 2025**

	2025		2024	
	€	€	€	€
Fixed assets		24,018		27,021
Current assets	340,554		279,470	
Prepayments and accrued income	2,000		2,000	
		342,554		281,470
Creditors: amounts falling due within one year		(168,005)		(135,420)
Net current assets		<u>174,549</u>		<u>146,050</u>
Total assets less current liabilities		198,567		173,071
Accruals and deferred income		(6,200)		(6,200)
Net assets		<u>192,367</u>		<u>166,871</u>
Capital and reserves		<u><u>192,367</u></u>		<u><u>166,871</u></u>

We, as directors of MAHONYS (PHARMACY) LTD. state that:

- (a) the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014;
- (b) the company is availing itself of the exemption on the grounds that the conditions specified in section 358 of the Companies Act 2014 are satisfied;
- (c) the shareholders of the company have not served a notice on the company under section 334(1) of the Companies Act 2014 in accordance with section 334(2);
- (d) we acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a financial year and to otherwise comply with the provisions of Companies Act 2014 relating to financial statements so far as they are applicable to the company; and
- (e) the company has relied on the specified exemption contained in section 352 of the Companies Act 2014; has done so on the grounds that the company is entitled to the benefit of that exemption as a micro company and the abridged financial statements have been properly prepared in accordance with section 353 of the Companies Act 2014.

The financial statements have been prepared in accordance with the micro companies regime.

These abridged financial statements were approved by the board of directors on 29 December 2025 and signed on behalf of the board by:

Mr. Michael Mahony
Director

Ms. Sinead Mahony
Director

MAHONYS (PHARMACY) LTD.

Notes to the abridged financial statements Financial year ended 31 August 2025

1. General information

The company is a private company limited by shares, registered in Ireland. The address of the registered office is 22/23 High Street,, Kilkenny..

2. Statement of compliance

These financial statements have been prepared in accordance with FRS 105, 'The Financial Reporting Standard applicable to the Micro-entities Regime'.

3. Accounting policies and measurement bases

Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 105 The Financial Reporting Standard applicable to the Micro-entities Regime issued by the Financial Reporting Council ("FRS 105"). The company qualifies as a micro company for the period, as defined by section 280D of the Companies Act 2014, in respect of the financial year and has applied the rules of the "micro companies regime" in accordance with section 280E of the Companies Act 2014 and FRS 105.

The financial statements are prepared in Euro and all amounts have been rounded to the nearest Euro which is the functional currency of the entity.

Turnover

Turnover is measured at the fair value of the consideration received or receivable for goods supplied and services rendered, net of discounts and Value Added Tax.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership have transferred to the buyer, usually on despatch of the goods; the amount of revenue can be measured reliably; it is probable that the associated economic benefits will flow to the entity and the costs incurred or to be incurred in respect of the transactions can be measured reliably.

Tangible assets

Tangible assets are measured initially at cost, and are subsequently stated at cost less accumulated depreciation and impairment losses.

Depreciation

Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:

Plant and machinery	- 10%
Fittings fixtures and equipment	- 12.5%

If there is an indication that there has been a significant change in depreciation rate, useful life or residual value of tangible assets, the depreciation is revised prospectively to reflect the new estimates.

MAHONYS (PHARMACY) LTD.

Notes to the abridged financial statements (continued) Financial year ended 31 August 2025

Impairment

A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date.

When it is not possible to estimate the recoverable amount of an individual asset, an estimate is made of the recoverable amount of the cash-generating unit to which the asset belongs. The cash-generating unit is the smallest identifiable group of assets that includes the asset and generates cash inflows that are largely independent of the cash inflows from other assets or groups of assets.

Stocks

Stocks are measured at the lower of cost and estimated selling price less costs to complete and sell. Cost includes all costs of purchase, costs of conversion and other costs incurred in bringing the stocks to their present location and condition.

Financial instruments

Ordinary Share Capital

The ordinary share capital of the company is presented as equity.

Cash and cash equivalents

Cash consists of cash on hand and demand deposits. Cash equivalents consist of short term highly liquid investments that are readily convertible to known amounts of cash that are subject to an insignificant risk of change in value.

Judgments

The directors consider the accounting assumptions below to be its critical accounting judgements:

Going Concern

The directors consider it appropriate to prepare the financial statements on a going concern basis despite the arrival of covid 19 in Ireland.

A financial asset or a financial liability is recognised only when the company becomes a party to the contractual provisions of the instrument.

Financial instruments are initially recognised at cost, which is the transaction price.

Defined contribution plans

Contributions to defined contribution plans are recognised as an expense in the period in which the related service is provided. Prepaid contributions are recognised as an asset to the extent that the prepayment will lead to a reduction in future payments or a cash refund.

When contributions are not expected to be settled wholly within 12 months of the end of the reporting date in which the employees render the related service, the liability is measured on a discounted present value basis. The unwinding of the discount is recognised in finance costs in profit or loss in the period in which it arises.

MAHONYS (PHARMACY) LTD.

**Notes to the abridged financial statements (continued)
Financial year ended 31 August 2025**

04. Appropriations of profit and loss account

	2025	2024
	€	€
At the start of the financial year	166,868	128,550
Profit for the financial year	25,496	38,318
At the end of the financial year	<u>192,364</u>	<u>166,868</u>

Directors ' transactions

The Directors have money loaned to the company. These loans are interest free, unsecured and repayable on demand. The balances thereon are included in current liabilities.

The net movements on the loans during the trading year are as follows :

	<u>Sinead</u>	<u>Michael</u>
Opening Balance at 01/09/2024	4,997	124,684
Repayments to directors (net)	5,408	-
Advances by directors (net)	-	18,876
Closing Balance at 31/08/2025	<u>10,405</u>	<u>143,560</u>